ANI Pharma legal chief sells 500 shares at $70.79

ANI Pharmaceuticals’ Senior Vice President, General Counsel & Secretary sold 500 ANIP shares under a pre-arranged Rule 10b5-1 trading plan and now holds 73,924 shares directly.

Available on EDGAR 09/14/2026 - 08:57 PM EDT Accepted by SEC EDGAR 09/14/2026 - 08:56 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANI PHARMACEUTICALS INC (ANIP) insider Meredith Cook, Senior Vice President, General Counsel & Secretary, reported selling 500 shares of common stock on September 14, 2026 at $70.79 per share. After this transaction, she directly holds 73,924 shares of ANI Pharmaceuticals common stock.

The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025, indicating the trade was made under a pre-arranged plan.

Insider Trade Summary 10b5-1

Net Seller: 500 shares

Net Sell 1 txn

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Sold 500 shs ($35K)

Share of Position Sold 0.67%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	500	$70.79	$35K

Holdings After Transaction: Common Stock — 73,924 shares (Direct)

Holdings Before and After: Common Stock, 74,424 to 73,924 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Key Figures

Shares sold: 500 shares Sale price per share: $70.79 per share Shares held after transaction: 73,924 shares +1 more

4 metrics

Shares sold 500 shares Common stock sale reported for September 14, 2026

Sale price per share $70.79 per share Price for the 500 ANIP shares sold on September 14, 2026

Shares held after transaction 73,924 shares Direct ownership of Meredith Cook following the reported sale

Rule 10b5-1 plan adoption date September 15, 2025 Date the trading plan governing this sale was adopted

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, common stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction market

"Sale in open market or private transaction"

common stock financial

"500 shares of ANI Pharmaceuticals common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANIP report for Meredith Cook?

Meredith Cook reported a sale of 500 shares of ANI Pharmaceuticals common stock on September 14, 2026 at $70.79 per share, leaving her with 73,924 shares held directly.

Was the ANIP insider sale by Meredith Cook under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Meredith Cook on September 15, 2025, indicating it was pre-arranged.

How many ANIP shares does Meredith Cook own after the reported sale?

After the reported transaction, Meredith Cook directly owns 73,924 shares of ANI Pharmaceuticals common stock, according to the Form 4 data.

What was the price for the ANIP shares sold by Meredith Cook?

The 500 shares of ANI Pharmaceuticals common stock were sold at a price of $70.79 per share, as reported in the Form 4.

What is Meredith Cook’s role at ANI Pharmaceuticals (ANIP)?

Meredith Cook is identified as Senior Vice President, General Counsel & Secretary of ANI Pharmaceuticals in the Form 4 reporting this insider transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S(1)		500	D	$70.79	73,924	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Remarks:

	/s/ Meredith W. Cook	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)